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Abstract
Cryoablation has been used for many years as a surgical ab-
lation technique in the prostate and kidney. However, since the
introduction of high-intensity focused ultrasound (HIFU) and
robotic surgery for prostate tumours, its popularity in the uro-
logic community has declined. In the early 2000s, innovations
in cryoablation technology allowed the use of thinner probes,
which were suitable for percutaneous application. As a result,
radiologists began using cryoablation, first in the liver, and
then in other organs or tissues such as the kidney, lung, breast,
pancreas, bone, and soft tissue. In most of these locations,
cryoablation has great potential given its inherent advantages,
including the use of local anaesthesia, little or no pain during
and after the procedure, real-time monitoring of the ablation
area on US, CT or MRI, the potential for ablation of large
tumours with multiple probes, and the ability to change the
shape of the ablation in non-spherical tumours. Yet despite
these advantages, the use of percutaneous cryoablation among
radiologists appears to be far lower than that of heat-based
ablation techniques. The aim of this article is to outline
specific aspects of cryoablation and to illustrate its potential
clinical applications with case presentations.
Key Points
• Recent advances have made cryoablation suitable for per-
cutaneous use by radiologists with image guidance.
• Cryoablation has distinct advantages over heat-based abla-
tion techniques.
• Cryoablation is becoming increasingly popular for lung,
breast, kidney, bone, and soft tissue tumours.
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Introduction
Cryoablation is a well-known ablation technique which uses
rapid freezing and thawing sequences for tissue destruction. In
the current third-generation devices, this is performed by rapid
decompression of argon gas (Joule–Thomson effect) and
thawing, either passively or by circulation of helium gas
through the probe. These freezing and thawing cycles cause
intracellular and extracellular ice crystal formation, intracellu-
lar dehydration, and ischemia due to vascular thrombosis, all
of which may result in necrosis or apoptosis [1, 2].
Percutaneous cryoablation is typically performed under
mild sedation and local anaesthesia. Cryoprobes are normally
inserted into the lesion under ultrasound (US) or computed
tomography (CT) guidance.
The number of probes depends on the size of the lesion,
and multiple probes are frequently necessary for the best cov-
erage. In a typical cryoablation procedure, a 10-min freezing,
5–10-min thawing, and 10-min freezing protocol is per-
formed, although other protocols have been used in some
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organs. During freezing, an iceball is formed around the
probes, which is generally visible on US, CT, and magnetic
resonance imaging (MRI) in all tissues except healthy bone.
The temperature at the outer surface of the iceball is 0 °C, with
cell death reliably occurring at a depth of 3–5 mm near the
edge. During the freezing process, the size and shape of the
iceball can be monitored to ensure that it covers the lesion
completely and is not near any critical structures. When nec-
essary, these structures can be protected by fluid, air, or bal-
loon interposition, or by reducing the power of the nearest
probe. During ablation, iceball formation can be monitored
with US, CT, or MRI. US provides real-time monitoring, but
only the superficial border of the iceball is visible. CT and
MRI provide excellent visualization of the iceball, but require
repeated scanning during the procedure. In general, US and
CT are preferred for the guidance and monitoring of
cryoablation, since MRI is less practical in light of the need
for special equipment and the limitations around the magnetic
field. US is usually sufficient for superficial lesions located in
noncritical areas such as the breast, thoracic and abdominal
wall, and liver, while CT is preferred in the lung, kidney, bone,
and deep visceral organs. In many clinical scenarios, the com-
bined use of US and CT may be the best solution for guiding
probe placement and iceball monitoring. After ablation is
completed, the probes are actively thawed with helium and
then removed. With some of the latest-generation probes, it
is also possible to perform track ablation at temperatures over
220 °C [1–4] (Fig. 1).
Cryoablation offers certain unique advantages over the other
ablation techniques. First, because of the natural anaesthetic
effect of the cold, the procedure can be performed under local
anaesthesia. This is important in cases where general anaesthe-
sia or deep sedation are dangerous for the patient, breath-
holding is desired during the procedure, or ablation is per-
formed in an office setting. In addition, patients experience
much less pain after treatment with cryoablation than with ra-
diofrequency. Second, in contrast to heat-based ablation
methods such as radiofrequency, microwave, or laser, tumours
larger than 3–5 cm in size can be reliably ablated with the use of
multiple probes (up to 25 probes can be used simultaneously).
Third, the iceball is readily visible on CT, MRI, and US, which
allows real-time monitoring of the ablation area. With clear
demonstration of the treatment margin, tumours close to critical
structures such as nerves, bowel, or bladder may be treated
confidently and with greater safety. And forth, cryoablation
causes less damage to collagen fibres, which makes it an attrac-
tive choice in tumours near critical structures [1–4].
However, cryoablation has twomajor disadvantages. First, it
is more expensive than other ablation methods, especially if
multiple probes are used. The use of argon and helium is an-
other factor that increases cost. And second, it is more time-
consuming than the other methods, which is particularly impor-
tant if multiple ablations are performed in the same session [1].
In the past, cryoablation was used almost exclusively by
surgeons, particularly urologists, mainly because the
commonest indication was prostate cancer and the probes
were large, required liquid nitrogen for cooling, and were
not well insulated, rendering them unsuitable for percutaneous
application [1, 5]. In the early 2000s, the introduction of thin-
ner argon-based probes with insulation along their shafts ush-
ered in the era of image-guided percutaneous cryoablation.
Radiologists first tested cryoablation in the liver; however,
due to the presence of already established methods such as
radiofrequency and associated complications such as
cryoshock, it was not widely used in this organ [2]. For the
last decade, the growing indication of percutaneous therapies
in oncology has enabled the use of cryoablation in other or-
gans and tissues, including the lung, kidney, breast, pancreas,
soft tissue, and bone [1–4, 6]. Although heat-based techniques
like radiofrequency and microwave have been more common-
ly used in these locations as well, cryoablation is increasingly
preferred given its unique features mentioned earlier. Yet there
is little data in the literature on the use of image-guided per-
cutaneous cryoablation by radiologists. This article reviews
Fig. 1 Some of the commercially available cryoprobes and the size, shape, and thermal aspects of their iceballs (Courtesy of Galil Medical)
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the indications and results of cryoablation in locations other
than the prostate, and highlights its advantages and disadvan-
tages compared to other ablation techniques.
Cryoablation in lung tumours
In early non-small cell lung cancer (NSCLC) and lung
oligometastases, the classic ablation technique is radiofre-
quency (RF) [7]. It is well-known, however, that due to the
high electrical resistance and poor thermal conductivity of
alveolar air, RF is less successful in the lung than in the liver.
Microwave ablation, another heat-based ablative technique,
has been proposed to overcome the limitations of RF. How-
ever, data on microwave ablation in the literature are sparse,
and high complication rates have been reported [7, 8].
Cryoablation has been successfully used within the last de-
cade in primary and secondary lung tumours, with 2-year local
progression-free survival rates of 60.7–100% in early NSCLC
and 45.6–80.4 % in metastases [9, 10]. In the lung, a triple-
freeze protocol is generally preferred to the classic dual-freeze
protocol, as the former was shown in an animal study to be
associated with faster and larger ablation [10].
The advantages of cryoablation in the lung include the
ability to perform the ablation under local anaesthesia with
breath-holding, which is important for successful ablation of
small lesions located near the diaphragm, as well as the visi-
bility of the ablation area (iceball) on CT and little or no pain
during or after the procedure [7–10] (Fig. 2). The absence of
major damage to collagen fibres makes cryoablation an attrac-
tive option for lesions located near the mediastinum, pericar-
dium, diaphragm, or pleura. In tumours that have infiltrated
the chest wall, cryoablation is superior to other ablation
methods in that it causes less pain and little damage to the
connective tissue [9].
Common complications of lung cryoablation are simi-
lar to those of RF and microwave, and include pneumo-
thorax, infection, and pleural fluid. However, haemoptysis
during or after the procedure is more common in
cryoablation [9], and is more likely to occur in central
lesions and when multiple cryoprobes are used. Since
haemoptysis may last for days or even weeks after abla-
tion, the use of antiaggregants or anticoagulants is not
appropriate during this period. Therefore, cryoablation
may not be a good choice in patients who depend on such
medications.
Fig. 2 Cryoablation of a lung
metastasis. a The sagittal cone
beam CT image shows a 7-mm
biopsy-proven colon cancer
metastasis (white arrow) and the
cryoablation needle (black
arrow). b Under local
anaesthesia, the cryoablation
needle is percutaneously inserted
into the lesion (black arrow). c
During ablation, an iceball
(arrowheads) is formed that
covers the lesion. d After 1 year,
the control CT image shows a
fibrotic remnant (white arrow) in
place of the tumour
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Cryoablation in the breast
The classic indication of cryoablation in the breast is
fibroadenoma. These benign tumours are quite common in
young women and do not require treatment in most cases. In
routine practice, however, surgery may be performed for
fibroadenomas that are large, symptomatic, or with atypical
US features. Since it may cause scarring and deformation, sur-
gery is not desirable for young women, particularly in the case
of multiple fibroadenomas [11]. Cryoablation, which was ap-
proved by the U.S. Food and Drug Administration (FDA) in
2002 for the treatment of fibroadenomas, is an excellent alter-
native in such cases. The procedure is painless, performed un-
der local anaesthesia, and able to treat multiple fibroadenomas
in the same session. Research has shown that more than 80 %
of fibroadenomas become non-palpable 1 year after
cryoablation [12] (Fig. 3).
An emerging indication of cryoablation is breast cancer. In
the last decade, percutaneous US-guided ablation has been
used successfully in the treatment of breast cancer [13–15].
Ideal patients for ablation are elderly women with small
(<2 cm) tumours and no axillary involvement or distant me-
tastasis. In patients with oligometastases, percutaneous
ablation is no longer considered contraindicated, provided that
they are also manageable percutaneously [13]. The most pop-
ular ablation methods in breast cancer are RF, cryoablation,
and high-intensity focused ultrasound (HIFU). Although
HIFU is completely non-invasive, it is not suitable for lesions
close to the skin or pectoralis muscle, requires expensive
equipment, and is associated with pain and long ablation
times, frequently requiring deep sedation or general anaesthe-
sia to keep the patient compliant. Therefore, RF and
cryoablation are more commonly used. Although their success
rates are similar, cryoablation has certain advantages. First, it
can be performed under local anaesthesia, which is important
for older patients. Second, the ablation area can be enlarged
with the use of multiple (generally 2–3) probes, which may
decrease the rate of local recurrence (Fig. 4). Third, the visi-
bility of the superficial border of the iceball on US enables
easier and more reliable skin protection. And fourth, because
it causes less damage to collagen tissue, pectoralis muscles are
generally unaffected during the ablation of deep lesions
[11–15]. A recent review including seven studies reported
short-term local control in 73 % of patients, with better results
in small (<15 mm) ductal tumours and when multiple cryo-
probes were used [16].
Fig. 3 Cryoablation of a
fibroadenoma. a The US image
shows a 31×21×16-mm
fibroadenoma (*) in the left breast
of a 33-year-old female. b The
cryoablation needle (black arrow)
is inserted percutaneously into the
lesion. c During ablation, the US
image shows the typical iceball
(arrowheads) encompassing the
lesion. The skin is protected by
external warming and
subcutaneous fluid injection. d
Seven months later, the follow-up
US shows marked shrinkage of
the fibroadenoma (*)
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Cryoablation in bone and soft tissue tumours
RF is the most common ablation method in bone and soft tissue
tumours [1, 17], and in recent years has become the gold stan-
dard in the treatment of osteoid osteoma [17]. Cryoablation is
also becoming increasingly popular for percutaneous ablation
of bone and soft tissue tumours. Although both cryoablation
and heat-based ablation techniques provide safe, effective, and
durable results, advantages such as real-time visibility of the
ablation area, the ability to treat large tumours with multiple
probes, and the absence of significant pain during and after the
procedure render cryoablation a more attractive alternative for
bone and soft tissue lesions [17–19] (Fig. 5).
Like any other ablation method, cryoablation must be used
with caution for lesions near the major nerves, especially in
the upper thoracic, neck, and pelvic regions. When necessary,
nerve protection techniques such as fluid, air, or carbon diox-
ide instillation, balloon interposition, or cryoprobe retraction/
torquing should be applied to prevent nerve injury. Because of
its superior visualization of the ablation zone, cryoablation is
superior to other methods for ablation of a tumour near a
critical nerve [17, 18].
Percutaneous cryoablation has been successfully used in the
palliation of painful bone metastases [19]. Although radiother-
apy is the standard treatment in these patients, it provides pain
relief in only about 60 % of cases, requires several weeks to
occur, and is often temporary. HIFU is an approved alternative
which, like radiotherapy, is non-invasive. Because ultrasound
energy is highly absorbed by the bone, the periosteal nerves are
easily destroyed, resulting in rapid pain relief. However, HIFU
cannot ablate the tumour under an intact periosteum, and there-
fore is less effective in deeply seated bone tumours. In contrast,
cryoablation can destroy both the periosteum and the tumour,
which may allow palliative as well as curative treatment, and
will likely produce more durable pain reduction. In weight-
bearing bones in the spine and pelvis, the combined use of
cementoplasty and cryoablation may provide additional pain
relief and reduce the risk of pathologic fracture [17, 19].
Cryoablation has recently been reported as an alternative
local treatment for desmoid tumours [17, 18]. Although com-
plete ablation was not always possible, cryoablation was prov-
en safe and effective for the local control of these difficult
tumours [18]. There are also reports in the literature of the
use of cryoablation in the treatment of aneurysmal bone cysts,
giant cell tumours, osteoid osteoma, non-ossifying fibroma,
and soft tissue vascular malformations [1, 16, 17]. Another
potential area for cryoablation is percutaneous neurolysis in
facet joint syndrome and degenerative spinal pain, although
RF is more commonly used for these indications [20].
Cryoablation has also been reported for the local control of
inguinal lymph node metastases [21]. Although RF is the
classic ablation method in lymph nodes, cryoablation may
be an attractive option in critical locations (Fig. 6).
Fig. 4 Cryoablation of breast cancer. a The PET-CT image shows a 2-cm
FDG-avid lesion (arrow) in the left breast, proven to be invasive ductal
carcinoma. The patient also has a 3-cm lytic metastasis in the right distal
femur (not shown). b Under local anaesthesia and US guidance,
cryoablation of the breast mass is performed using three cryoneedles. c
Two months later, the follow-up PET-CT shows complete metabolic re-
sponse in the lesion (arrow). The ablation area was then percutaneously
removed with vacuum biopsy, which revealed fibrosis and fat necrosis
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Cryoablation in renal tumours
With the widespread use of cross-sectional imaging such as
CT and MRI, incidental small (<4 cm) renal tumours are
increasingly detected. Since these tumours are diagnosed at
an early stage (generally 1A) and generally in the elderly,
percutaneous ablation is a suitable option. In the last decade,
both RF and cryoablation have been used extensively to treat
small renal cell carcinoma (RCC). The classic indications for
renal ablation are comorbid conditions preventing surgery,
contralateral recurrence, and hereditary precancerous condi-
tions. The long-term (5–10 years) results with these tech-
niques have shown an oncologic outcome equal to that of
surgery, with fewer complications and less decline in renal
function [22–25].
In the past, renal cryoablation was a Bsurgical^ proce-
dure, typically performed laparoscopically by urologists
[22]. With the introduction of argon-based thin probes in
the 2000s, radiologists—who were already performing
image-guided RF ablation for renal tumours—also began
performing percutaneous renal cryoablation [24, 25].
Studies comparing laparoscopic and percutaneous
cryoablation have shown oncologic results that were sim-
ilar, but the latter had lower rates of complications. Stud-
ies comparing RF ablation with cryoablation found simi-
lar results in terms of oncologic outcome and complica-
tion rates. The types of complications, however, differed
slightly between these two techniques: chyluria was more
common with RF, and bleeding was more common with
cryoablation, both of which were treated conservatively
[23–25]. A unique advantage of cryoablation is the visi-
bility of the ablation area (iceball) and the potential for
safe displacement of tissue using air-filled balloons,
which are not harmed by the ice (Fig. 7).
Cryoablation in adrenal tumours
Primary adrenal tumours such as functioning adenoma
and carcinomas are normally treated with laparoscopic
adrenalectomy, with percutaneous ablation limited to
cases unsuitable for surgery [26]. In adrenal metastases
(isolated or oligometastatic), percutaneous image-guided
ablation has a well-established role, and has been per-
formed using RF, microwave, and cryoablation with
similar success [26–28].
The procedure is typically performed under CT guidance
with the patient in prone or lateral decubitus position (Fig. 8).
One specific complication of adrenal ablation is hypertensive
crisis, for which pre- and peri-procedural alpha and beta
blockers are recommended [26, 27]. In RF and microwave
procedures, the hypertensive crisis occurs during the ablation,
and is more pronounced with microwave, since the tissue is
heated more rapidly. In cryoablation, the hypertensive crisis is
generally less aggressive and typically occurs during thawing
[27, 28].
Fig. 5 Cryoablation of bone metastasis (the solitary metastasis in the
distal femur of the previous patient). a, b First, under local anaesthesia
and US guidance, three bone biopsy needles are inserted into the lesion
under cone-beam CT guidance, and cryoablation is then performed with
needles (arrows) inserted coaxially. c After the ablation, the cryoneedles
are removed, and cement (arrowheads) injection is performed through the
outer needles to support the bone
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Cryoablation in liver tumours
Cryoablation has been extensively used in liver tumours,
particularly in difficult cases such as those located in sub-
capsular, subdiaphragmatic, or central regions [29]
(Fig. 9). Although successful results have been reported
in both hepatocellular carcinoma (HCC) and colorectal me-
tastases [29, 30], several factors limit its use in the liver.
First, cryoablation can cause what is referred to as the
cryoshock phenomenon, which is a cytokine-mediated sys-
temic reaction characterized by hypotension, disseminated
intravascular coagulopathy, and multiorgan failure.
Cryoshock is generally seen after cryoablation of large
(>5 cm) hepatic tumours and is frequently fatal. Second,
since the liver is a well-perfused organ, there is a signifi-
cant Bcold sink^ effect, which results in a smaller iceball.
Thus, a greater number of needles are required to obtain a
certain ablation size, which may increase both cost and risk
of complications. And third, heat-based ablations such as
RF and microwave are highly successful in the liver, and
are also safer and cheaper. Therefore, these systems are
currently considered the gold standard in primary and
metastatic liver tumours, and cryoablation is reserved for
select cases [29–31].
Cryoablation in other locations
Cryoablation has also been reported in the literature for pancre-
atic cancer [32, 33]. Although RF has been more commonly
used, and irreversible electroporation has recently become pop-
ular in pancreatic cancer, both techniques have been associated
with significant risk of complications [34, 35]. Pancreatic
cryoablation, on the other hand, was found to be safer, with
delayed gastric emptying the only reported complication [32].
In general, virtually any solid tumour in a location suitable
for percutaneous ablation can be treated with cryoablation.
Hypervascular tumours, however, are likely not good candi-
dates for cryoablation, as iceball formation is limited due to
the cold sink effect, and the use of multiple probes carries a
greater risk of vascular complications such as bleeding and
arteriovenous fistula. In such cases, heat-based ablation may
be more suitable, as the vessels are occluded during heating
and track ablation.
Fig. 6 Cryoablation of a
peripancreatic lymph node. a In a
44-year-old patient after surgical
treatment of ovarian carcinoma,
PET-CT image shows a lymph
node metastasis (white arrow)
near the pancreas. Since the
metastasis was solitary,
percutaneous ablation was
planned, and because of the
critical location of the lesion,
cryoablation was preferred. b
Under local anaesthesia and US+
CT guidance, a cryoablation
needle (black arrow) was inserted
transhepatically into the lesion. c
The lymph node was ablated with
two freeze and one thaw cycle,
and an iceball was typically seen
(arrowheads). Since the liver was
traversed, track ablation was
performed after cryoablation to
prevent bleeding and tumour
seeding. d Eight months later, the
follow-up CT shows complete
metabolic response of the lesion
(white arrow)
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Conclusion
After a long history of urologic use and a decline in popularity,
cryoablation is back again as an image-guided percutaneous
technique, thus providing an opportunity for radiologists. In this
article, we tried to summarize the classic and emerging
indications of percutaneous cryoablation in various organs,
and to emphasize its advantages and limitations in comparison
to heat-based ablation. In many tumours, cryoablation may be
preferable to other ablation methods, given advantages such as
the use of local anaesthesia, less pain during and after the pro-
cedure, visibility of the ablation area on US, CT, and MRI, the
Fig. 7 Cryoablation of recurrent
renal cancer. a The axial contrast-
enhanced CT image shows an
exophytic renal tumour (white
arrow) next to the descending
colon. The patient had undergone
ipsilateral partial nephrectomy for
RCC 6 months earlier. b, c Under
local anaesthesia and US+BT
guidance, two cryoneedles are
inserted percutaneously (black
arrows) into the lesion. The
tumour is separated from the
descending colon with an
angioplasty balloon (yellow
arrow) inserted percutaneously
through a sheath. d, e Axial and
reformatted CT images show the
iceball (arrowheads) covering the
tumour and the two cryoablation
needles. During the 1.5-year
follow-up, there was no evidence
of tumour recurrence
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potential to ablate large tumours with multiple probes, and the
ability to change the shape of the ablation in non-spherical
tumours. As pioneers in image-guidedminimally invasive treat-
ments, radiologists should take advantage of these unique fea-
tures of cryoablation for the percutaneous treatment of tumours.
Fig. 8 Cryoablation of a surrenal gland metastasis. a The PET-CT image
shows an FDG-avid lesion (white arrow) in the right surrenal gland. The
patient had undergone surgery for rectal cancer 1 year earlier. b During
the cryoablation, the tilted axial image shows the ablation needle (yellow
arrow) directed towards the lesion (arrow). c One year after the
cryoablation, the follow-up PET-CT shows no evidence of tumour
Fig. 9 Cryoablation in the liver. a The axial PET-CT image shows a
subcapsular FDG-avid lesion (white arrow). The patient had previously
undergone surgery for cholangiocarcinoma, and the biopsy showed the
lesion to be metastatic cholangiocarcinoma. b Cryoablation was
performed under US and cone-beam CT guidance, which shows the
iceball (arrowheads) produced by two cryoneedles covering the lesion.
Another needle (black arrow) was also inserted for fluid injection to
separate the adjacent transverse colon from the tumour. c One year
later, the control PET-CT image shows complete metabolic response in
place of the lesion
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